DUPIXENT is not a steroid. DUPIXENT is a biologic and can help reduce your patients’ use of systemic corticosteroids.¹

In the SINUS-24 and SINUS-52 trials in adults, there was an 83% reduction in the need for sinus surgery with DUPIXENT 300 mg Q2W + INCS vs placebo + INCS through Week 52 (HR: 0.17 [95% CI: 0.07, 0.46]).^1,a 

DUPIXENT 300 mg Q2W + INCS provided a 74% reduction in the need for SCS use through Week 52 vs placebo + INCS (HR: 0.26 [95% CI: 0.18, 0.38]).¹

DUPIXENT 300 mg Q2W + INCS provided a 76% reduction in the need for SCS use and/or sinus surgery through Week 52 vs placebo + INCS (HR: 0.24 [95% CI: 0.17, 0.35]).^1,4,a,b

^aIndividually, SCS reduction and need for sinus surgery were not multiplicity-adjusted endpoints.^1,4

^b In SINUS-24 and SINUS-52, DUPIXENT 300 mg + INCS (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo + INCS (Day 0: n=286; Week 24: n=187; Week 52: n=61).¹

HR, hazard ratio; INCS, intranasal corticosteroid; Q2W, once every 2 weeks; SCS, systemic corticosteroid.